Summary

The 7 major osteosarcoma markets reached a value of US$ 880.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,456.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2024-2034.

The osteosarcoma market has been comprehensively analyzed in IMARC's new report titled "Osteosarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Osteosarcoma is a form of cancer in which the cells that develop new bones produce a cancerous tumor. The disease is more common in the adolescent age group and usually develops in the long bones, often the legs and arms. The symptoms of the ailment can vary from person to person but include swelling and redness at the tumor site, pain or tenderness in the bone or joint, limited movement, limping, etc. Some people may experience unexplained fever and broken bones, along with a lump or mass in the affected area. Osteosarcoma can also spread to other parts of the body, such as the lungs, which can cause symptoms like coughing, shortness of breath, and chest pain. The diagnosis usually involves a combination of medical history, physical examination, and imaging tests. Various imaging studies, including X-rays, magnetic resonance imaging (MRI), computed tomography (CT), etc., are used to detect abnormalities in the bone and surrounding tissue. A biopsy is also typically performed to confirm the presence of cancerous cells and determine the type and extent of the cancer. In some cases, blood tests may be used to assess the levels of certain enzymes and proteins that are associated with osteosarcoma.

The rising prevalence of several associated risk factors, including genetic mutations, radiation exposure, Paget's disease of bone, previous bone injuries, etc., is primarily driving the osteosarcoma market. In addition to this, the increasing utilization of non-invasive imaging techniques, such as MRI and CT scans, since they can provide detailed images of the bone and surrounding tissue and help clinicians better evaluate the extent of the cancer, is also augmenting the market growth. Moreover, the widespread adoption of targeted therapy, including kinase inhibitors and monoclonal antibodies, which boost the immune response against tumor cells without harming the healthy cells, is acting as another significant growth-inducing factor. Moreover, numerous key players are making extensive investments in developing novel ways to deliver drugs directly to cancer cells while limiting damage to healthy tissue. This, in turn, is also creating a positive outlook for the market. Additionally, the emerging popularity of molecular profiling technology, including next-generation sequencing and immunohistochemistry, which helps identify precise gene or chromosome changes associated with the tumor, is further bolstering the market growth. Besides this, the escalating application of combination therapy involving neoadjuvant chemotherapy and surgical resection, that reduces the risk of cancer relapse and improves treatment outcomes in patients, is expected to drive the osteosarcoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the osteosarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for osteosarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the osteosarcoma market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the osteosarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the osteosarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current osteosarcoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the osteosarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the osteosarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the osteosarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of osteosarcoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of osteosarcoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of osteosarcoma by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of osteosarcoma by type across the seven major markets?
How many patients are diagnosed (2018-2034) with osteosarcoma across the seven major markets?
What is the size of the osteosarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of osteosarcoma?
What will be the growth rate of patients across the seven major markets?

Osteosarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for osteosarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the osteosarcoma market?
What are the key regulatory events related to the osteosarcoma market?
What is the structure of clinical trial landscape by status related to the osteosarcoma market?
What is the structure of clinical trial landscape by phase related to the osteosarcoma market?
What is the structure of clinical trial landscape by route of administration related to the osteosarcoma market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Osteosarcoma - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034​)
4.4 Market Overview (2018-2023) and Forecast (2024-2034​)
4.5 Competitive Intelligence

5 Osteosarcoma - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Osteosarcoma - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034​)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034​)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034​)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034​)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034​)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034​)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034​)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034​)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)

8 Osteosarcoma - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Osteosarcoma - Unmet Needs

10 Osteosarcoma - Key Endpoints of Treatment

11 Osteosarcoma - Marketed Products
11.1 List of Osteosarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Osteosarcoma - Pipeline Drugs
12.1 List of Osteosarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 ALMB-0168 - AlaMab Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Lenvatinib - Eisai Co Ltd/Merck & Co
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Znc3 - Zentalis Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Camrelizumab - Jiangsu Hengrui Medicine
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ZKAB001 - Lee's Pharmaceutical/Sorrento Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Osteosarcoma - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Osteosarcoma – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Osteosarcoma - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Osteosarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034​)
15.2.2 Osteosarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034​)
15.3 Market Scenario - United States
15.3.1 Osteosarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034​)
15.3.2 Osteosarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034​)
15.3.3 Osteosarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Osteosarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034​)
15.4.2 Osteosarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034​)
15.4.3 Osteosarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Osteosarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034​)
15.5.2 Osteosarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034​)
15.5.3 Osteosarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Osteosarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034​)
15.6.2 Osteosarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034​)
15.6.3 Osteosarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Osteosarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034​)
15.7.2 Osteosarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034​)
15.7.3 Osteosarcoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Osteosarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034​)
15.8.2 Osteosarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034​)
15.8.3 Osteosarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Osteosarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034​)
15.9.2 Osteosarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034​)
15.9.3 Osteosarcoma - Access and Reimbursement Overview

16 Osteosarcoma - Recent Events and Inputs From Key Opinion Leaders

17 Osteosarcoma Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Osteosarcoma Market – Strategic Recommendations

19 Appendix